Targeting a specific receptor in tumors with CAR T cells
OR2H1 is an effective target for CAR T cells in human epithelial tumors
This study is working on a new type of treatment using specially designed immune cells to target a specific receptor found in certain tumors, like bile duct and prostate cancers, with the hope of making it safer and more effective for patients who have these types of cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10896142 on NIH RePORTER |
What this research studies
This research focuses on developing CAR T cells that specifically target the OR2H1 receptor found in various human tumors, including cholangiocarcinomas and prostate cancers. By genetically engineering these CAR T cells, the goal is to enhance their effectiveness while minimizing harmful side effects associated with targeting receptors present in vital organs. The research will involve preclinical studies to demonstrate the safety and efficacy of these CAR T cells before moving towards human clinical trials. Patients with tumors expressing the OR2H1 receptor may benefit from this innovative treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with tumors that express the OR2H1 receptor, such as intrahepatic cholangiocarcinoma or prostate cancer.
Not a fit: Patients whose tumors do not express the OR2H1 receptor are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, targeted therapy for patients with specific types of cancer, potentially improving treatment outcomes and reducing side effects.
How similar studies have performed: Other research has shown promise in using CAR T cell therapies targeting specific tumor antigens, indicating a potential for success with this novel approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Conejo-Garcia, Jose R — Duke University
- Study coordinator: Conejo-Garcia, Jose R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.